Ishara Investments LP Invests $1.31 Million in Oric Pharmaceuticals, Inc. $ORIC

Ishara Investments LP purchased a new position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 160,000 shares of the company’s stock, valued at approximately $1,309,000. Oric Pharmaceuticals makes up about 1.5% of Ishara Investments LP’s holdings, making the stock its 23rd largest position. Ishara Investments LP owned about 0.16% of Oric Pharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. Engineers Gate Manager LP acquired a new position in shares of Oric Pharmaceuticals during the 4th quarter worth $85,000. Boothbay Fund Management LLC raised its holdings in shares of Oric Pharmaceuticals by 97.2% during the 4th quarter. Boothbay Fund Management LLC now owns 218,610 shares of the company’s stock worth $1,788,000 after buying an additional 107,777 shares in the last quarter. Freestone Grove Partners LP acquired a new position in shares of Oric Pharmaceuticals during the 4th quarter worth $198,000. Logos Global Management LP acquired a new position in shares of Oric Pharmaceuticals during the 4th quarter worth $3,681,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Oric Pharmaceuticals during the 4th quarter worth $117,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

Oric Pharmaceuticals Stock Up 3.9%

Shares of ORIC opened at $8.63 on Thursday. Oric Pharmaceuticals, Inc. has a 12-month low of $7.23 and a 12-month high of $14.93. The business has a 50-day simple moving average of $9.00 and a two-hundred day simple moving average of $10.09. The stock has a market cap of $893.38 million, a PE ratio of -5.99 and a beta of 1.04.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, May 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, equities research analysts expect that Oric Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ORIC. Benchmark reissued a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. The Goldman Sachs Group raised Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Tuesday, April 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a report on Friday, May 22nd. Finally, Citigroup lowered their target price on Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.92.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.